In 1974 when I was a third year medical student on my very first clinical rotation (vascular surgery), I was following a recently retired mechanical engineer who suffered from claudication, which is cramping of his leg due to insufficient blood flow. This was preventing him from enjoying his retirement, as he could only walk a short distance before his leg cramped. This condition is caused by an obstruction of the femoral artery to the affected leg. Today, that would be safely treated with a stent to open the obstruction. But this occurred before such procedures existed. His obstruction was treated with a vein bypass graft from his femoral artery, above the obstruction, to the artery in the back of the knee, which is called the popliteal artery. The procedure was familiarly called a “fem-pop” bypass. He was supposed to go home the following afternoon.
However, that did not happen. This gentleman bled to death overnight from an undetected (occult) internal bleed into his abdomen, probably due to a vessel that was nicked at the time of the surgery. I was horrified and promised myself that I would find out how such an event could occur in a university hospital and, with my personal background in electrical engineering, if there might be a technical solution that could alert the medical staff so they could act in time to prevent such a serious outcome.
So-how could it happen? The reason is that when a patient is losing blood, the body goes into a state called “compensated shock” in which the blood pressure (BP) is preserved by powerful reflexes that shut down the blood flow to non-vital organs such as the skin, muscle, kidney, gut and liver, essentially shrinking the vascular space to match the amount of blood that is left in it. These reflexes are so effective that a patient has to lose 40% of their blood volume before their BP starts to fall. But this brings the patient perilously close to cardiovascular collapse, which can be fatal, as it was for this patient. As hard as it is to believe, today, in 2026, there is still no way to know that a patient has life threatening internal bleeding without waiting for hours to see if urine output or the blood count noticeably drop. In fact, as strange as it may seem, in 2026, the best way to know that a patient is having severe internal bleeding is to feel their foot and see if it’s cold.
I got the idea that maybe, if we could monitor the blood flow to a non-vital organ, such as the muscle on an arm or leg, we could “help” the body tell us that it was entering compensated shock. This turned out to be a fortunate guess. I invented a machine called a “Pulse Flowmeter” that non-invasively measures blood flow to the muscle on a limb using a soft electrode that wraps around the limb much like a blood pressure cuff. With that machine, we were able to detect the loss of a single unit of blood in blood donors at the Red Cross. One unit of blood is about 8% of the blood volume, way below the 40% required to drop the BP. I formed a startup company, MGI Medical, to commercialize the device.
The blood donor study was encouraging but I still wasn’t sure that the machine would perform well in a true clinical environment where patients are being moved around, have BP cuffs inflating and deflating and are getting intravenous fluids. I couldn’t imagine doing a study of postop patients because it would take thousands of cases before there would be enough bleeders to allow a statistical analysis to be performed. This troubled me for a few years and I seemed stuck. Then, as luck would have it, I met a young woman at a family event who had just completed her residency in emergency medicine. When I told her of my dilemma, she told me the ER docs have a great deal of difficulty triaging patients who present with GI bleeding because they have no way of knowing if they are still actively bleeding or not. As a result, almost all GI bleeders are admitted to the hospital for observation but only about 20% of them end up needing an intervention. These needless admissions run up a pretty steep bill! She asked me if my machine could detect the presence or absence of internal bleeding and I said that it might, but we’d have to do a clinical trial to see if it would work for this purpose.
A couple of weeks later I called the GI department at the Mayo Clinic. The head of their bleeding unit saw the potential benefit of our Pulse Flowmeter and asked me to come to Rochester, Minnesota to demonstrate the machine for them. My chief engineer and I went there a couple of weeks later. The Mayo folks saw the potential of the and assigned a team of researchers to study it. The study was pretty simple; the limb flow was measured when the patient was admitted and then followed until they returned from getting an endoscopy which allowed the doctors to directly visualize the GI tract to see if there was active bleeding. The results were better than we could have dreamed. In every single one of the 12 subjects in the study, we were able to predict whether or not they would find active bleeding at the endoscopy,
With that result, I finally became convinced that this was a clinical tool with real potential value. I was then able to bring on board an experienced, successful med-tech entrepreneur as our CEO. He has positioned us so that we can make a credible case to investors that this will become a successful product, one that may become “standard-of-care” meaning that its use would be required on all GI bleeders, surgical patients and trauma victims.
I’m a pediatric cardiologist and have taken care of tens of thousands of children with suspected or actual heart disease. This has been a privilege that I cannot overstate. But I am hoping that I will have an enduring professional legacy by bringing the Pulse Flowmeter into the world where it will probably save thousands of lives.
If you are a young person starting your career, I would like to tell you that it has been over 50 years since I saw the need for such a device and over 40 years since I built the first prototype (on an Apple 2E computer with floppy disks)! My message to you is that persistence toward a goal is as important, maybe even more so, than any other characteristic in bringing a new technology to market. And our adventure is still not over as we have just started seeking investors so we can complete the journey.
Lloyd Marks, MD, MBA, FACC, FAIMBE
Founder and Medical Director
908-347-2662

